0.01Open0.01Pre Close0 Volume9.15K Open Interest2.50Strike Price0.00Turnover286.39%IV243.84%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type0.0609Delta0.2517Gamma73.08Leverage Ratio-0.0015Theta0.0000Rho4.45Eff Leverage0.0002Vega
Vaxart Stock Discussion
Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
— 400 subject sentinel portion of Phase 2b study will evaluate the safety, immunogenicity and efficacy of Vaxart's next generation oral pill COVID-19 vaccine compared to an approved mRNA vaccine comparator —
— The sentinel cohort is being funded as part of the Phase 2b NextGen COVID-19 clinical trial, valued at up to $456 million through the Rapid Response ...
Analyst writes that Vaxart's oral tablet could offer better immunity than traditional intramuscular vaccines, which have faced challenges.
Oppenheimer initiated with an Outperform rating and a price target of $4, representing significant potential upside.
“VXRT is uniquely positioned as a leading company developing oral vaccines against COVID-19, supported by one of the largest BARDA-funded Project NextGen Awards,” the analyst writes.
“We think oral vaccines hold unique proper...
After hours, we can see this going to $1.05 and possibly $1.15
can see $1.15 coming
direct hit 🎯 $1.0
time to fly, looking for $1
No comment yet